Indian drugmaker Gujarat Themis Biosyn Ltd. has obtained private credit funding to back its purchase of Japanese peer MicroBiopharm Japan Co., highlighting the growing use of such debt for overseas expansion in Asia.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.